-
Surrogate BBB Model Corrects Lysosomal Trapping
2026-08-19
Hu and colleagues developed a high-throughput LLC-PK1-MOCK/MDR1 Transwell model that combines barrier integrity testing, P-glycoprotein transport measurements, and correction for lysosomal drug sequestration. Across 41 compounds, the platform correlated in vitro permeability with unbound brain distribution and improved interpretation of compounds with low recovery.
-
A 83-01: From TGF-β Blockade to Translation
2026-08-18
A mechanistic and strategic guide to using A 83-01 as an ALK-5 inhibitor in TGF-β pathway assays, trophoblast differentiation, EMT research, fibrosis models, and translational experimental design.
-
BAPTA for Calcium Signaling and Apoptosis
2026-08-18
BAPTA is a high-affinity calcium chelator for testing whether intracellular Ca2+ is a cause, rather than merely a consequence, of cellular injury. This guide translates a nanoplastic–cadmium apoptosis study into practical workflows for calcium signaling modulation, pathway mapping, and assay troubleshooting.
-
Perphenazine in Neuropharmacology and Host Defense
2026-08-17
Perphenazine combines dopamine D2 receptor antagonism with a broad phenothiazine receptor profile, making it useful for neuropharmacology, mitochondrial toxicity, and host-directed antibacterial assays. This guide translates published findings into practical workflows, controls, and troubleshooting decisions for reproducible laboratory research.
-
WP1066: JAK2/STAT3 Logic Beyond Oncology
2026-08-17
WP1066 is more than a cancer-pathway probe: it offers a cell-permeable way to test when JAK2/STAT3 activity sustains malignant behavior and when the same signaling axis supports regenerative macrophage function. This thought-leadership perspective connects oncology validation with bone-regeneration biology while defining practical controls, translational boundaries, and next-step experiments.
-
BCKAs Activate HIF1α Signaling in Vascular Cells
2026-08-16
The reference preprint identifies branched-chain α-ketoacids as paracrine metabolites that activate HIF1α signaling in vascular cells despite ambient oxygen. Its findings connect BCKA metabolism to PHD2 inhibition, L2HG production, glycolytic remodeling, and pulmonary artery smooth muscle cell phenotype, providing a mechanistic framework for pulmonary vascular disease research.
-
10074-G5: Practical c-Myc Inhibitor Workflows
2026-08-15
Build reproducible cancer research assays around 10074-G5, a small-molecule c-Myc/Max dimerization inhibitor suited to viability, apoptosis, cell-cycle, and pathway studies. This guide connects product handling with the MYC/TERT/NFκB biology reported in esophageal adenocarcinoma and emphasizes controls, timing, and troubleshooting.
-
Imatinib hydrochloride Research Workflows
2026-08-15
Build reproducible CML and GIST experiments with Imatinib hydrochloride, from DMSO stock preparation to phospho-signaling validation. A conformational-control concept from recent kinase–phosphatase research adds a practical way to distinguish direct kinase blockade from downstream dephosphorylation effects.
-
Ibotenic Acid: NMDA Models and Workflow Tips
2026-08-14
Ibotenic acid is a versatile NMDA receptor agonist for controlled circuit perturbation, neurotoxicity studies, and neurodegenerative disease modeling. This guide translates dose- and time-dependent mouse toxicity findings into practical preparation, assay-selection, troubleshooting, and quality-control strategies.
-
TPPU: Soluble Epoxide Hydrolase Inhibitor Workflows
2026-08-14
TPPU enables nanomolar interrogation of sEH-dependent lipid signaling in inflammatory pain, osteoclast, and liver–bone studies. This guide connects assay design, sample handling, pharmacodynamic readouts, and troubleshooting to help researchers distinguish target engagement from nonspecific effects.
-
Lipo3K Transfection Reagent: Practical Workflow Guide
2026-08-13
Build reliable DNA, mRNA, siRNA, and multiplexed assays with a low-toxicity lipid transfection reagent designed for adherent, suspension, and difficult-to-transfect cells. This guide connects Lipo3K workflows with pH-responsive antisense research, emphasizing practical controls, optimization, and interpretation limits.
-
Measuring Drug Response in Cancer In Vitro
2026-08-13
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. By separating growth inhibition from cell killing and considering their timing, the work provides a more informative framework for interpreting in vitro cancer pharmacology.
-
Phenothiazines, ROS, and Macrophage Antibacterial Defense
2026-08-12
Qiu et al. report that phenothiazines strengthen macrophage control of intracellular bacteria by increasing reactive oxygen species, lysosomal activity, and autophagy. Perphenazine also reduced organ injury and inflammation in a Salmonella Typhimurium infection model, supporting phenothiazines as lead compounds for host-directed antibacterial research.
-
pH-Sensitive Nanoparticles Reverse BCSC Drug Resistance
2026-08-12
The reference study developed SchB/AP nanoparticles to combine ATRA-based tumor-cell targeting with schisandrin B-mediated reversal of multidrug resistance in breast cancer stem cells. Its in vitro findings link pH-responsive release, lysosomal escape, reduced P-glycoprotein activity, and altered drug-efflux energy supply to improved cytotoxicity against resistant cells.
-
Rotigotine and Bladder Function in Parkinson’s Rats
2026-08-11
The reference study shows that rotigotine produces route-dependent changes in bladder activity in a 6-hydroxydopamine rat model of Parkinson’s disease. Its central contribution is to connect dopaminergic pharmacology with cystometric measures of overactive bladder, while also highlighting why acute injection data should not be directly equated with transdermal treatment.